No abstract available.
Drug Therapy* ; Tuberculosis, Pulmonary*

Background: Pulmonary tuberculosis is a contagious bacterial infection that mainly involves the lungs, but may spread to other organs. Most people who develop symptoms of a tuberculosis infection first became infected in the past. However, in some cases, the disease may become active within weeks after the primary infection. Objective: To evaluate the diagnosis and treatment of pulmonary tuberculosis. Subjects and method: A retrospective study included 196 patients with pulmonary tuberculosis hospitalized in Department of Respiratory of Bach Mai Hospital in 2 years (2002 - 2003). Patients\ufffd?information of medical records was collected. Results and conclusions: 60.7% of patients were male and 39.3% were female. Tuberculous pleurisy was 59%, parenchymal lung tuberculosis 36%, and the others 5%. Clinical signs and symptoms included chest pain 67.9%, dyspnea 61.2%, cough 72.9% (nonproductive cough: 42.3%; productive cough: 30.6%), fever 61.2%. Dull to flat percussion, decreased to absent breath sound and fremitus 65.3% (89% tuberculous pleurisy). 27.6% of patients had positive AFB evident (smear, bronchial lavage fluid). The first line drugs were usually used in treatment of tuberculosis.
Tuberculosis ; Pulmonary/ diagnosis ; therapy

Tuberculous cavity is important in diagnosis and observation in the course of pulmonary tuberculosis. Authoranalyzed the radiologic findings of cavity and average months of negative conversion in AFB culture in 89 cases ofinitial treatment. The results were as follows: 1. The more number of cavities, the longer period in negativeconversion of AFB culture. 2. No relation between sums of diameter and thickeness of cavity and average months ofnegative conversion in AFB cultlure. 3. In the cases of cavity with air-fluid level took longer period in negativeconversion of AFB culture than those of cavity without air-fluid level, significantly. 4. No relation betweenradiologic findings of cavity and results of chemotherapy for pulmonary tuberculosis.
Diagnosis ; Drug Therapy ; Tuberculosis, Pulmonary

No abstract available.
Drug Therapy* ; Family Practice* ; Humans ; Tuberculosis, Pulmonary*

Numerous problems has not been solved in the field of pulmonary tuberculosis, especially in chemotherapy. There has been many turning points in the treatment of pulmonary tuberculosis such as; introduction of streptomycin, combination therapy, isoniazid single therapy, intermittent chemotherapy, and recent short-term chemotherapy. It is very important to know about individual drugs for the better chemotherapy. So a review has been made referring many literatures in pharmacologic properties of them. Also single INH therapy, double chemotherapy and triple chemotherapy have be described.
Drug Therapy* ; Isoniazid ; Streptomycin ; Tuberculosis, Pulmonary

The preliminary results showed that the immunotherapy with M.Vaccae may be very effective. 13 of 20 patients without immunotherapy (group A) have improved clinically, comparing with 22 improved patients of 22 patients with immunotherapy (group B), especially, 4 of 20 patients in group A had a relapse after treatment, and the difference of immune responses between 2 groups in the end of treatment could be found out.
Tuberculosis, Pulmonary ; Immunotherapy ; Drug Therapy ; Diagnosis

These days, genitourinary tuberculosis (GUTB) rarely occurs in conjunction with pulmonary tuberculosis. Reconstructive surgery for GUTB has also decreased but may still be done in case of a grossly distorted genitourinary anatomy and dysfunction that are unlikely to regress with chemotherapy alone. Reconstructive bladder surgery for GUTB is a well-established procedure. The various complications associated with the reconstructive surgery have also been well documented. We present a case of an uncommon complication after ileocystoplasty.
Drug Therapy ; Tuberculosis* ; Tuberculosis, Pulmonary ; Tuberculosis, Urogenital ; Urinary Bladder* ; Urinary Diversion

BACKGROUND: Interferon-gamma (IFN-g) and tumor necrosis factor-alpha (TNF-a) play a critical role in protective immunity against Mycobacterium tuberculosis infection. (The change )of IFN-g and TNF-a producing capacity in the course of antituberculous chemotherapy in patients with pulmonary tuberculosis (was evaluated in this study.) METHOD: In 29 patients with pulmonary tuberculosis, phytohemagglutinin(PHA) or purified protein derivative(PPD) stimulated production of IFN-g and TNF-a by peripheral blood mononuclear cells was quantified. Five patients were sampled before they underwent antituberculous treatment, 11 patients after 0 -4 months, six after 4 -completion and seven after treatment completion. RESULT: There was no difference in PHA- or PPD- stimulated production of IFN-g and TNF-a between each group. CONCLUSION: No difference in PHA- or PPD- stimulated production of IFN-g and TNF-a between two groups could be identified during classification of patients with pulmonary tuberculosis by their treatment stages.
Classification ; Drug Therapy* ; Humans ; Interferon-gamma ; Mycobacterium tuberculosis ; Tuberculosis ; Tuberculosis, Pulmonary* ; Tumor Necrosis Factor-alpha

Intestinal tuberculosis presents with nonspecific and variable clinical manifestations. It is rarely seen in current clinical practice and the diagnosis may be missed or confused with many other disorders such as Crohns disease and intestinal neoplasms. The route of infection by tuberculous enteritis is variable and the treatment regimens used for treating pulmonary tuberculosis are generally effective for tuberculous enteritis as well. Uncomplicated tuberculous enteritis can be managed with a nine to 12- month course of antituberculous chemotherapy. If not treated early, the prognosis for intestinal tuberculosis is poor, with an overall mortality of between 19 percent and 38 percent. However, 90 percent of patients will respond to medical therapy alone if started early. Therefore, early detection and treatment is essential. Here we report a case of intestinal tuberculosis secondary to miliary tuberculosis.
Crohn Disease ; Diagnosis ; Drug Therapy ; Enteritis ; Humans ; Intestinal Neoplasms ; Mortality ; Prognosis ; Tuberculosis* ; Tuberculosis, Miliary* ; Tuberculosis, Pulmonary

BACKGROUND: Cervical tuberculous lymphadenitis(CTL) is one of the most common extra-pulmonary tuberculosis. Recently overall incidence of pulmonary tuberculosis has decreased, but the incidence of tuberculous lymphadenitis has not decreased. Its duration of treatment is still controversial and the pathogenesis, prognosis and relationship with other site tuberculous are poorly published. So we did a retrograde study of 120 cases of confirmed CTL about its clinical manifestations. METHODS: All patients were applied fine needle aspiration(FNA) of palpable enlarged cervical lymph nodes and 114 patients were examined for AFB smear and 34 patients for TB culture with aspirated fluid. 57 patients were examined Mantoux test(5TU with PPD-S). With above methods, a total of 120 patients was diagnosed as having CTL RESULTS: 1) CTL is most prevalent in young women between the age of 20 30 years and the incidence of CTL in female is 2.5 times higher than that of male. It is located most commonly in the posterior cervical area. The most common presenting symptom is painless palpable enlarged cervical lymph nodes. 2) With FNA of enlarged cervical lymph nodes, the percentage of histopathological positivity is 82.3%. The percentage of AFB smear positivity is 38.6%, and that of TB culture positivity is 17.6% (p<0.001). 3) Pulmonary tuberculosis is noted in 79 cases(65.8%). And 42 cases(53.5%) of them had minimal pulmonary tuberculosis. In 14 cases(11.7%),other extrapulmonary tuberculosis coexsisted and pleural tuberculosis was most common in the order. 4) CTL was treated with anti-tuberculous medication(first line drug) and median treatment duration was 18.5months. During treatment, the size of involved lymph nodes decreased gradually in 62 cases(75.8%), newly developed lymph nodes were found in 25 cases(30.4%),fluctuation formation in 22 cases(26.8%) and fistula formation in 14 cases(17.0%). CONCLUISON: CTL is prevalent in women between the age of 20 ~ 40 years and it involves posterior cervical area most commonly. CTL is treated with long-term anti-tuberculous chemotherapy. We think it is one manifestation of systemic disease and frequently coexisting with pulmonary tuberculosis. Despite anti-tuberculous chemotherapy, the size of involved lymph nodes was increased, new lymph nodes were developed or fluctuation and fistula formed in involved lymph nodes. After sufficient medication, when the patient felt pressure discomfort from enlarged lymph node or fistula was formed, we recommended total excision of involved lymph nodes.
Drug Therapy ; Female ; Fistula ; Humans ; Incidence ; Lymph Nodes ; Male ; Needles ; Prognosis ; Tuberculosis ; Tuberculosis, Lymph Node* ; Tuberculosis, Pleural ; Tuberculosis, Pulmonary